New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 19, 2013
19:03 EDTSYNSynthetic Biologics reiterates collaboration with Intrexon still in effect
Synthetic Biologics reiterated that the exclusive channel collaboration agreement dated August 6, 2012 between the company and Intrexon remains in effect. This agreement governs a "channel collaboration" arrangement for the use of Intrexon's technology relating to the identification, design and production of human antibodies and DNA vectors for the development and commercialization of a series of monoclonal antibody therapies for the treatment of certain serious infectious diseases.
News For SYN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 1, 2015
07:02 EDTSYNSynthetic Biologics' SYN-004 shows positive results supporting development
Synthetic Biologics announced clinical data supporting the development of SYN-004, the company's candidate therapy designed to degrade certain beta-lactam intravenous antibiotics within the gastrointestinal tract and maintain the natural balance of the gut microbiome for the prevention of C. difficile infection, antibiotic-associated diarrhea and secondary antibiotic-resistant infections. These data support expanding the development of therapeutics designed to protect the microbiome from all beta-lactam antibiotics for the prevention of C. difficile infection, beyond penicillins and cephalosporins. The U.S. Centers for Disease Control and Prevention has categorized C. difficile as an "urgent public health threat". SYN-004 is intended to block the unintended harmful effects of antibiotics within the GI tract and maintain the natural balance of the gut microbiome. Approximately 118 million doses of IV beta-lactam antibioticsiii that could be inactivated in the GI tract by SYN-004, were administered to approximately 14 million hospitalized U.S. patients during 2012.
March 30, 2015
06:58 EDTSYNSynthetic Biologics initiates Phase 2a clinical trial of SYN-004
Subscribe for More Information
March 22, 2015
11:13 EDTSYNSynthetic Biologics has lunch meeting with Philadelphia Securities Association
Subscribe for More Information
March 19, 2015
09:20 EDTSYNOn The Fly: Pre-market Movers
Subscribe for More Information
06:58 EDTSYNSynthetic Biologics announces positive PK results from SYN-004 trials
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use